Skip to main content

Table 4 Comparison of the prevalence rate of PPO among theĀ control and intervention groups

From: The impact of a multifaceted intervention to reduce potentially inappropriate prescribing among dischargedĀ older adults: a before-and-after study

Type of PPOs according to START criteria

Control Group N (%)

Intervention group N (%)

Cardiovascular System

ā€ƒ ā€œVitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial fibrillationā€

2 (0.8)

7 (2.9)

ā€ƒ ā€œAntiplatelet therapy with a documented history of coronary, cerebral or peripheral vascular diseaseā€

10 (4.2)

5 (2.1)

ā€ƒ ā€œStatin therapy with a documented history of coronary, cerebral or peripheral vascular diseaseā€

11 (4.6)

11 (4.6)

ā€ƒ ā€œAngiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery diseaseā€

30 (12.5)*

16 (6.7)*

ā€ƒ ā€œBeta-blocker with ischaemic heart diseaseā€

22 (9.2)

16 (6.7)

ā€ƒā€œAppropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failureā€

6 (2.5)

6 (2.5)

Respiratory System

ā€ƒ ā€œRegular inhaled Ɵ2 agonist or antimuscarinic bronchodilator mild to moderate asthma or COPDā€

11 (4.6)

17 (7.1)

ā€ƒ ā€œRegular inhaled corticosteroid for moderate-severe asthma or COPDā€

10 (4.2)

6 (2.5)

Musculoskeletal System

ā€ƒ ā€œVitamin D supplements in older people who are housebound or experiencing falls or with osteopeniaā€

37 (15.4)**

14 (5.8)**

ā€ƒ ā€œXanthine-oxidase inhibitors with a history of recurrent episodes of goutā€

2 (0.8)

3 (1.3)

Endocrine System

ā€ƒ ā€œACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal diseaseā€

20 (8.3)

29 (12.1)

Urogenital System

ā€ƒ ā€œAlpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessaryā€

9 (3.8)

6 (2.5)

ā€ƒ ā€œ5-alpha-reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessaryā€

12 (5.0)

9 (3.8)

  1. COPD chronic obstructive pulmonary disease.
  2. *pā€‰=ā€‰0.03; **pā€‰=ā€‰0.001